Elimination of Antibiotics During Renal Replacement Therapy and Cytosorb Adsorptive Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-12-01

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cytokine adsorption using the cytosorb adsorber is currently investigated to reduce the levels of proinflammatory cytokines in patients with severe sepsis and septic shock. The adsorber is frequently used in series with continuous renal replacement therapy. Up to date, no data on the removal of antibiotic drugs during combined renal replacement therapy and cytokine adsorptive therapy is available. Therefore, we want to investigate

\- whether and to what extent antibiotic drugs (piperacillin/tazobactam and imipenem/cilastatin) are removed during combined continuous renal replacement therapy and cytosorb adsorption in patients with severe sepsis and septic shock

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Elimination of Antibiotics During Citrate-anticoagulated Continuous-veno-venous-haemodialysis

NCT02533609

Acute Kidney Injury Bacterial Infection

UNKNOWN

Cytokine Adsorption in Sepsis and Acute Kidney Injury

NCT02588794

Renal Insufficiency or Renal Failure &or End-stage Renal Disease

UNKNOWN NA

Investigating Different Anticoagulants for Renal Replacement Therapy

NCT02669589

Acute Kidney Injury

COMPLETED PHASE4

Citrate-based Regional Anticoagulation Versus Heparin for Continuous Renal Replacement Therapy

NCT01269112

Acute Kidney Injury

COMPLETED PHASE4

Continuous Renal Replacement Therapy With Oxiris in Acute Kidney Injury and Sepsis

NCT06253377

Acute Kidney Injury Sepsis

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients in this trial are undergoing renal replacement therapy as part of their routine care. Thus, this is an observational trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Critical Illness Sepsis Acute Kidney Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Piperacillin/Tazobactam

Critically ill patients teated with piperacillin/tazobactam undergoing renal replacement therapy and cytosorb absorption during sepsis

Monitoring of antibiotic drug removal

Intervention Type OTHER

No study specific intervention will be performed

Imipenem/Cilastatin

Critically ill patients teated with imipenem/cilastatin undergoing renal replacement therapy and cytosorb absorption during sepsis

Monitoring of antibiotic drug removal

Intervention Type OTHER

No study specific intervention will be performed

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Monitoring of antibiotic drug removal

No study specific intervention will be performed

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Intensive care patients with severe sepsis or septic shock and acute kidney injury requiring continuous renal replacement therapy and cytokine adsorption
* Age \> 18 y